Cingulate Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cingulate Inc. on August 6, 2025. The Company is a Delaware corporation with its principal executive offices in Kansas City, KS. It is classified as an emerging growth company. The report primarily addresses a significant regulatory milestone regarding its lead pharmaceutical asset.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than periodic financial performance data.
Material Changes and Events
- NDA Submission: On July 31, 2025, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
- Asset Details: The application is for CTx-1301 (dexmethylphenidate), the Company's lead asset intended for the treatment of attention deficit/hyperactivity disorder (ADHD).
- Disclosure: The Company issued a press release on August 6, 2025, to announce this submission under Regulation FD.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the inherent uncertainty of FDA review processes. The information provided is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
Investor Verification Checklist
- Verify the status of the NDA for CTx-1301 (dexmethylphenidate) via the FDA database.
- Review the full text of the press release attached as Exhibit 99.1 for additional clinical data or context.
- Confirm the Company's cash runway and liquidity position in the most recent 10-Q or 10-K, as this 8-K does not contain financial statements.
- Monitor for FDA responses or requests for additional information regarding the NDA submission.